Is higher serum cholesterol associated with altered tendon structure or tendon pain? A systematic review by Tilley, D et al.
Is higher serum cholesterol associated with
altered tendon structure or tendon pain?
A systematic review
Benjamin J Tilley,1 Jill L Cook,1,2 Sean I Docking,1,2 James E Gaida1,3,4
▸ Additional material is
published online only. To view






2Australian Centre of Research


















Accepted 18 June 2015
To cite: Tilley BJ, Cook JL,
Docking SI, et al. Br J Sports
Med 2015;49:1504–1509.
ABSTRACT
Background Tendon pain occurs in individuals with
extreme cholesterol levels (familial hypercholesterolaemia).
It is unclear whether the association with tendon pain is
strong with less extreme elevations of cholesterol.
Objective To determine whether lipid levels are
associated with abnormal tendon structure or the
presence of tendon pain.
Methods We conducted a systematic review and meta-
analysis. Relevant articles were found through an
electronic search of 6 medical databases—MEDLINE,
Cochrane, AMED, EMBASE, Web of Science and Scopus.
We included all case–control or cross-sectional studies
with data describing (1) lipid levels or use of lipid-
lowering drugs and (2) tendon structure or tendon pain.
Results 17 studies (2612 participants) were eligible for
inclusion in the review. People with altered tendon
structure or tendon pain had signiﬁcantly higher total
cholesterol, low-density lipoprotein cholesterol and
triglycerides, as well as lower high-density lipoprotein
cholesterol; with mean difference values of 0.66, 1.00,
0.33, and −0.19 mmol/L, respectively.
Conclusions The results of this review indicate that a
relationship exists between an individual’s lipid proﬁle
and tendon health. However, further longitudinal studies
are required to determine whether a cause and effect
relationship exists between tendon structure and lipid
levels. This could lead to advancement in the
understanding of the pathoaetiology and thus treatment
of tendinopathy.
INTRODUCTION
Tendinopathy is the term used to describe painful
tendon conditions.1 While the exact pathoaetiology
of tendinopathy remains unclear,2 overuse is consid-
ered as a major contributing factor.3 Despite this
link, approximately one-third of cases occur in non-
active individuals.4 Obesity and fat distribution have
been associated with tendinopathy,5–7 with one
explanation being that higher body mass causes
increased tendon loading (mechanical hypothesis).7
However, increased body mass index (BMI) has also
been linked with tendinopathy in the non-weight-
bearing upper limbs,8 which suggests that a mechan-
ical hypothesis does not sufﬁciently explain changes
to tendon structure or onset of tendon pain.6 There
is growing evidence for a metabolic hypothesis
linking BMI and tendinopathy.
A well-known comorbidity of obesity is hyper-
cholesterolaemia, an established risk factor for cor-
onary heart disease.9 Cholesterol also accumulates
in tendons, where it may be involved in structural
disruption of the collagen matrix, similar to that
seen in tendinopathy.10–12 This has been demon-
strated in patients with familial hypercholesterol-
aemia (FH), a genetic lipid metabolism disorder
that is characterised by lifelong elevation of serum
cholesterol.13 Substantial cholesterol deposition
occurs in FH and is known as tendon xanthoma.14
While many medical textbooks state that tendon
xanthomas are asymptomatic, data show a sixfold
increase in the lifetime incidence of Achilles tendon
pain associated with FH.15
Chronic low-grade inﬂammation (para-inﬂamma-
tion) is a critical driver of cardiovascular disease
(CVD) and is also a predominant feature of FH.16 17
The instigating event in CVD is retention of
apolipoprotein-B containing lipoproteins beneath the
endothelial layer of the blood vessel wall18 where
they are irreversibly modiﬁed via interaction with
extracellular matrix proteoglycans.19 Subendothelial
lipoprotein retention triggers the release of chemo-
kines, which promote monocyte recruitment and
conversion to macrophages.17 As these macrophages
ingest and process retained lipoproteins, they accu-
mulate cytoplasmic lipid droplets, and under the
microscope these droplets look like soap bubbles,
leading to the term ‘foam cells’.20 Eventually choles-
terol esteriﬁcation and efﬂux mechanisms are over-
whelmed and the excess cholesterol becomes
cytotoxic.21 Each of these steps contributes to the
para-inﬂammation present in CVD and FH.22
Recent studies of non-ruptured tendinopathy
tissue indicate subtle increases in mast cells and
macrophages23 24 although other studies ﬁnd no
such increase.25 26 When the clinician is consider-
ing this new information, it is critically important
to remember that para-inﬂammation is triggered by
subtle alterations in tissue homeostasis rather than
infection and trauma, which are the familiar trig-
gers of acute (triphasic) inﬂammation.27 Therefore,
para-inﬂammation is not triggered by a bout of
unresolved acute inﬂammation but is a response to
tissue stress that is maintained over an extended
period of time.27 Similarly, archetypal proinﬂam-
matory cytokines (eg, tumour necrosis factor alpha)
can have anti-inﬂammatory effects via alternate sig-
nalling pathways.26
Other studies have identiﬁed associations
between cholesterol and tendon rupture28 29 and
chronic tendinopathy.6 Together, these data build
support for the metabolic hypothesis as an explan-
ation for the presentation of tendinopathy among
sedentary individuals.
A systematic review by Gaida et al7 revealed that
a relationship exists between adiposity and tendino-
pathy. As an abnormal lipid proﬁle is commonly
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associated with obesity,30 this research has provided a basis for a
closer examination of this relationship. Thus, the primary aim
of this systematic review was to investigate whether there is an
association between abnormal lipid levels and changes in tendon
structure or tendon pain. A secondary aim was to describe the
association that lipid-lowering drugs have with tendon structure




Six electronic databases (MEDLINE, Cochrane, AMED, Web of
Science, Scopus and EMBASE) were searched in April 2014.
Medical subject headings used in the search included (1) Tendons,
Tendon Injuries, Tendinopathy, Xanthomatosis AND (2) Lipids,
Lipoproteins, Cholesterol, Hydroxymethylglutaryl-CoA Reductase
Inhibitors and Lovastatin. Free text terms were also searched with
appropriate truncation, and included (1) tendon structure, tendon
thickness, tend#nopathy, tend#nos#s, tendon pain and (2) lipid,
cholesterol, high-density lipoprotein, low-density lipoprotein, tri-
glyceride, statin, hydroxymethylglutaryl-CoA reductase inhibitors
(for complete list of search terms, see online supplementary
appendix A). All records were then imported into reference man-
agement software (Endnote version X5).
Eligibility criteria
One author (BT) applied predeﬁned eligibility criteria to the
title and abstracts of the retrieved records. To be included
studies had to provide data on both lipid levels or lipid-lowering
drugs and tendon structure or tendon pain. We excluded case
reports, case series and retrospective studies, reviews, letters,
conference abstracts, comments, editorials, non-English articles,
and studies of non-human, cadaver or biopsy material. Papers
that involved participants with cerebrotendinous xanthomas,
inﬂammatory or systemic arthritis, or FH were excluded.
However, FH papers were included if they presented tendon
data from a non-FH control group. In the second round of
reviewing, the full text was read to determine whether the
article met the inclusion and exclusion criteria.
Quality assessment
Included papers were assessed for methodological quality to
identify potential sources of bias. A tool was developed by the
authors based on the quality assessment criteria developed by
Downs and Black (see online supplementary appendix B).31 The
tool consisted of 11 criteria, each addressing a different source
of bias. An explicit decision rule was developed for each criter-
ion to improve precision. Quality assessment results were con-
verted to a percentage score as not all studies could be marked
on all criteria.
Data extraction and study analysis
Data were extracted by one author (BT) and included study
details, participant demographics, tendon outcomes, lipid out-
comes, and any results presented (ie, effect size, odds ratio
(OR)). If data for the lipid levels of participants were presented
in milligrams per decilitre (mg/dL), these units were converted
to millimole per litre (mmol/L) using appropriate calculations
(see online supplementary appendix C). When necessary, data
were extracted from ﬁgures using Engauge Digitilizer (Mitchell,
M; V.4.1) (see online supplementary appendix C).
Meta-analysis was conducted on appropriate data using
RevMan (The Cochrane Collaboration; V.5.1). A random effects
model was used with inverse variance weighting, and results
presented as mean difference (MD). A meta-analysis was con-
ducted for each of the four lipid measurements (total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C) and triglycerides (TG)), and their
individual association with tendon structure or tendon pain.
RESULTS
The databases search yield of 1607 papers was imported into
Endnote and 561 duplicates were removed. The title and
abstract of 1046 papers were reviewed and 962 studies were
removed. The full text version of 84 papers was reviewed and
67 studies were removed. In the end, 17 studies were included
in the review (ﬁgure 1).
The quality of the included papers showed considerable vari-
ation, with the mean quality assessment score being 62% (range
20–82%), suggesting that the current literature in this area is of
moderate quality (see online supplementary appendix D). The
majority of studies reported their method of participant recruit-
ment; however, these participants were not commonly represen-
tative of the population from which they were recruited. The
case–control nature of all but one of these studies explains why
the two groups were often taken from different populations.
With the exception of Ozgurtas et al,29 authors reported that
controls were free from disease. The majority of authors pre-
sented a control group that was matched to the case group with
respect to potential confounding factors. Reporting the method
used to assess tendon structure was a common criteria met by
these papers, however, these methods were not always identical
for cases and controls. Only one study6 reported assessor blind-
ing, with the remainder of the studies having the potential for
assessor bias.
Fifteen of the included papers used a case–control study
design, and two used a cross-sectional design (table 1). Imaging
was used to deﬁne tendon structure in 14 studies—7 used ultra-
sound, 2 used MRI, 1 used CT and 4 used radiography.
A variety of methods were used to assess tendon symptoms,
including palpation, clinical history and a visual analogue scale
for pain. The tendons examined included rotator cuff (n=4)
and Achilles tendon (n=13).
Figure 1 Flow chart of search yield and study selection.
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Among the case–control papers, there were ﬁve studies that
recruited the case group based on tendon structure or tendon
pain,6 29 32–34 and three studies that recruited the case group
based on lipid abnormalities.35–37 There were seven studies of
FH where only the control group was included.13 14 38–42 Two
studies examined the cross-sectional relationship between
tendon health and lipid proﬁles.8 43 In three of the ﬁve studies
that recruited based on tendon structure or tendon pain, signiﬁ-
cant differences in lipids or statin use were identiﬁed. In two of
the three studies that recruited on lipid levels, signiﬁcant differ-
ences in tendon pain or structure were identiﬁed.
Data were extracted from all 17 papers in the review
(see online supplementary appendix E), of which ﬁve were
pooled for meta-analysis.6 8 29 32 34 These papers used lipid
levels as the continuous variable, for both case and control
tendon health groups. The non-FH control groups from the
seven FH studies13 14 38–42 were not included in the
meta-analysis. Achilles tendon thickness (ATT) was used as a
continuous outcome variable in two studies that each had a high
and a low lipid group,35 37 however one of these investigated
men and women separately and so the two could not be com-
pared against each other. Two studies provided dichotomous
data on tendon pathology; however one paper investigated the
association with lipid levels,36 while the other examined the
association with statin use,33 thus the papers were presented
separately. Finally, one paper was a cross-sectional study and so
could not be compared to the case–control studies.43
TC and tendon pathology
TC was signiﬁcantly higher among individuals with tendon pain
or rupture, MD=0.66 mmol/L, 95% CI 0.11 to 1.21 (ﬁgure 2).
HDL-C and tendon pathology
HDL-C was signiﬁcantly lower among individuals with tendon
pain or rupture, MD=−0.19 mmol/L, 95% CI −0.30 to −0.07
(ﬁgure 3).
LDL-C and tendon pathology
LDL-C was signiﬁcantly higher among individuals with tendon
pain or rupture, MD=1.00 mmol/L 95% CI 0.23 to 1.77
(ﬁgure 4).
TG and tendon pathology
TG was signiﬁcantly higher among individuals with tendon pain
or rupture, MD=0.33 mmol/L, 95% CI 0.15 to 0.50 (ﬁgure 5).
Lipid level and tendon pathology
One paper36 recorded the prevalence of tendon pathology
(history of Achilles tendinitis or tendon xanthomas) in a group
with mixed hyperlipidaemia and a normolipidaemic control
group. Tendon pathology was present in 18 (75%) of those with
mixed hyperlipidaemia, compared with none of the normolipi-
daemic participants.
Table 1 Study details
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Abate (2014) Cross-sectional study Italy Neither—referred for LL disease UL Structure
Abboud (2010) Case–control study USA Tendon structure UL Structure
Beri (2009) Case–control study USA Tendon structure Both Structure
Descamps (2001) Case–control study Belgium Lipid levels LL Structure
Durrington (1982) Case–control study UK Lipid levels LL Structure
Gaida (2009) Case–control study Australia/Sweden Tendon pain LL Both
Gattereau (1973) Case–control study Canada Lipid levels LL Structure
Junyent (2005) Case–control study Spain Lipid levels LL Structure
Klemp (1993) Case–control study South Africa Lipid levels Both Both
Kwak (2013) Case–control study Korea Lipid levels LL Structure
Longo (2010) Case–control study UK Tendon structure Both Both
Mabuchi (1977) Case–control study Japan Lipid levels LL Structure
Mabuchi (1978) Case–control study Japan Lipid levels LL Structure
Ozgurtas (2003) Case–control study Turkey Tendon structure LL Structure
Rechardt (2013) Cross-sectional study Finland Tendon pain UL Pain
Tsouli (2009) Case–control study Greece Lipid levels LL Structure
Yuzawa (1989) Case–control study Japan Lipid levels LL Structure
Figure 2 Forest plot showing the relationship between total cholesterol levels and tendon pathology (TC, total cholesterol).
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Lipid level and ATT
Tendon thickness was used as the continuous variable in two
studies,35 37 looking for differences between the hyperlipid-
aemic case group and the normolipidaemic control group.
However, the paper by Gattereau et al35 analysed men and
women separately and did not provide data for the population
as a whole, and so the results could not be compared with the
paper by Kwak et al.37 Interestingly, as the former split the par-
ticipants into men and women, this paper allowed an investiga-
tion of whether or not this association was greater in one sex
compared with the other.
Gattereau et al35 used cut-off values for TC and TG of 240 and
140 mg/dL, respectively, to separate the hyperlipidaemic group
from the normolipidaemic group. Hyperlipidaemic subjects were
found to have a signiﬁcantly increased ATT compared to the nor-
molipidaemic controls. This was evident for both men (standar-
dised MD (SMD)=0.95, 95% CI 0.19 to 1.71) and women
(SMD=0.86, 95% CI 0.13 to 1.58). A signiﬁcant positive correl-
ation between cholesterol and ATT was also found, with correl-
ation coefﬁcients of 0.85 for women and 0.63 for men.
Kwak et al37 used the European Society of Cardiology deﬁnition
for dyslipidaemia (any one of the following: TC >240 mg/dL, TG
>200 mg/dL, LDL-C >160 mg/dL, HDL-C <40 mg/dL). There
was no signiﬁcant difference in ATT between the dyslipidaemic
(0.44±0.04 cm) and control group (0.45±0.02 cm, p=0.783).
There was also no signiﬁcant correlation between ATT and lipid
parameters. The coefﬁcients for TC was −0.09 (p=0.36), HDL-C
−0.06 (p=0.50), LDL-C −0.03 (p=0.69) and TGs −0.04
(p=0.63).
Statins and tendon rupture
One paper33 examined the association between statin therapy
and tendon structure. Statin use was the same in those with and
without tendon rupture, however, preplanned subgroup analysis
showed an increase in tendon rupture in women taking statins,
OR=3.09 (95% CI 1.04 to 9.75). No increased risk was identi-
ﬁed in men, OR=0.62 (95% CI 0.3 to 1.3).
ATT and lipid levels in FH studies
Seven FH papers with a non-FH control group were
included.13 14 38–42 Each paper presented data on ATT and lipid
proﬁles, but only one40 analysed this relationship in the control
group, ﬁnding a moderate positive correlation (r=0.454, p<0.01).
Lipid parameters from the remaining studies were pooled using
appropriate equations (see online supplementary appendix F;44
ﬁgures 6–10).
Lipid levels and pain intensity
There was only one study43 that used pain intensity as an
outcome. This was a study of the association of obesity and
metabolic parameters with upper extremity pain. Age-adjusted
and gender-adjusted ORs of pain intensity was calculated for
TC, HDL-C, LDL-C and TG. A high pain intensity was asso-
ciated with both low HDL-C levels (OR 2.7, 95% CI 1.2 to
6.3) and high TG levels (OR 2.8, 95% CI 1.3 to 6.6; table 2).
DISCUSSION
This systematic review showed with meta-analysis that people
with altered tendon structure had signiﬁcantly higher TC,
Figure 3 Forest plot showing the relationship between high-density lipoprotein cholesterol levels and tendon pathology (HDL-C, high-density
lipoprotein cholesterol).
Figure 4 Forest plot showing the relationship between low-density lipoprotein cholesterol levels and tendon pathology (LDL-C, low-density
lipoprotein cholesterol).
Figure 5 Forest plot showing the relationship between triglyceride levels and tendon pathology (TG, triglycerides).
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LDL-C and TG, as well as lower HDL-C, than people with
normal tendons. Individuals with an adverse lipid proﬁle were
much more likely to have tendon pathology, and to have higher
pain intensity associated with upper limb musculoskeletal injury.
Statin use was associated with Achilles tendon rupture in
women but not men. Finally, two of the three studies that corre-
lated ATTwith lipid parameters found a signiﬁcant positive cor-
relation. Together, these ﬁndings provide signiﬁcant support for
a metabolic hypothesis of tendon injury and implicate lipid
parameters as a potential link.
While the data in this review indicate a link between lipid
parameters and tendon health, causation cannot be established
from cross-sectional data. As tendon injury limits physical activ-
ity, reverse causation—tendon injury causing elevated lipids—is
possible given that metabolic parameters rapidly deteriorate
with complete bed rest45 and reduced daily steps.46 However,
observational and mechanistic studies suggest that adverse lipid
parameters can be harmful to tendons. For example, individuals
with FH have altered tendon structure in childhood and adoles-
cence,47 and aggressive lipid treatment reduces tendon thick-
ness.14 Furthermore, mechanistic studies show that
hyperlipidaemia alters the mechanical properties of tendon
across several species.48 49 Together, these data provide plausi-
bility for lipid parameters leading to reduced tendon health,
suggesting that reverse causation is unlikely.
High cholesterol promotes the accumulation of cholesterol in
macrophages and other immune cells, which drives para-
inﬂammation. Downstream signalling pathways trigger a reduction
in cholesterol efﬂux,22 which increases cholesterol accumulation
and maintains the para-inﬂammation state.22 These processes
provide a potential explanation for a link between hypercholester-
olaemia and tendinopathy. Supporting this hypothesis is the
increased number of mast cells and macrophages shown in those
with tendinopathy, compared with a healthy control popula-
tion.23 24 Additionally, the strong inﬂammatory phenotype of
FH16 suggests that a state of para-inﬂammatory change may be
involved in the mechanism of high cholesterol leading to tendino-
pathy.16 It is unclear whether these processes also occur in
tendons, particularly given the magnitude of hypercholesterol-
aemia noted in association with tendinopathy (eg, 5.7±1.2,
pooled mean of cases from ﬁgure 2) is far less than that observed
in FH (eg, 8.3±1.0 mmol/L).14
A secondary aim of this review was to examine whether statin use
was correlated with tendon structure. One eligible paper33 investi-
gated this association and found, in an a priori subgroup analysis,
that women taking statins had an increased risk of tendon rupture.
Recent evidence suggests this effect may be mediated by changes in
the proﬁle of metalloproteinase enzymes within the tendon.50
These enzymes are involved in remodelling the extracellular matrix
of tendon and have been linked with tendon rupture.51
Pain intensity was used as an outcome in one paper43 and was
found to be associated with low HDL-C and high TG among
individuals with upper extremity soft tissue disorders. This
study pooled participants with a range of diagnoses, including
tendinopathy of the rotator cuff, lateral elbow and wrist ﬂexor
tendons. Grouping diagnoses is, in one sense, a limitation of the
study; however, this approach allowed the authors to collect a
large sample of participants with a recent onset of pain
(<1 month). The strong association of LDL-C and TG with
recent onset pain provides strong, but obviously not deﬁnitive,
evidence against reverse causation.
The lipid changes associated with tendon injury parallel those
associated with CVD, namely, TC, LDL-C and TG are increased
Figure 6 Achilles tendon thickness (ATT) mean (SD).
Figure 7 Total cholesterol (TC) mean (SD).
Figure 8 High-density lipoprotein cholesterol (HDL-C) mean (SD).
Figure 9 Low-density lipoprotein cholesterol (LDL-C) mean (SD).
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while HDL-C is decreased. This suggests that tendon and artery
respond to their metabolic environments in similar ways. Both
are collagen-based tissues, capable of responding to their
loading environment. For example, branch points and bifurca-
tions of arteries are exposed to shear forces created by turbu-
lence,52 have an altered proteoglycan content, and are prone to
atherosclerosis development.53 The pathogenesis of atheroscler-
osis is driven by long-standing para-inﬂammation, involving the
recruitment and conversion of monocytes to macrophages.54
The macrophages accumulate cholesterol esters to form ‘foam
cells’, which play a central role in the formation of atheroscler-
otic lesions.54 In tendons, shear and compression forces alter
the proteoglycan proﬁle,55 and these areas are prone to path-
ology. There is evidence that proteoglycan (particularly those
with a chondroitin sulfate side chain) precipitates cholesterol
accumulation within both tendon and artery through its strong
afﬁnity for cholesterol.56 57 In short, things that are bad for
your heart also seem to be bad for tendons.
There are limitations of this review that should be acknowl-
edged. One limitation was that 17 potentially relevant
non-English studies were excluded. Language bias has been
demonstrated for randomised trials58—studies with signiﬁcant
ﬁndings are more likely to be published in English-language
journals—and may also affect observation studies such as those
included in this review. Limitations are also inherent in the data
set used for this review. For example, the included studies used
a variety of methods to assess tendon structure or tendon pain.
Blood lipid analysis is a standardised laboratory procedure with
little potential for systematic bias. Blood collection procedures,
however, may introduce bias. For example, in the study by
Ozgurtas et al,29 blood samples were collected from the case
group within 6 h of tendon rupture, while those from the
control group were collected after an overnight fast. While this
is not ideal, large datasets show minimal difference between
fasting and non-fasting lipid measurements.59
CONCLUSION
The review comprehensively identiﬁed all available data on the
potential link that lipid fractions have with tendon pain and
structure. The meta-analysis supports an association for TC,
HDL-C, LDL-C and TG. A potential mechanism for this link is
the para-inﬂammation that is present in FH. Ongoing research
is required to determine whether similar processes occur in the
presence of less extreme cholesterol elevations associated with
lifestyle factors. Notwithstanding this, the current work indi-
cates that there is indeed an association between unfavourable
changes in lipid parameters and tendinopathy.
Summary box
▸ This review identiﬁed 17 studies on the topic of tendon
health and lipid proﬁle. Five studies compared lipid proﬁle
between individuals with and without tendon pain/
abnormality, and three studies compared tendon health
between individuals with and without lipid abnormality. The
cross-sectional relationship between tendon health and lipid
proﬁle was examined in two studies. Seven studies on
familial hypercholesterolaemia provided data from their
healthy control group.
▸ Meta-analysis of appropriate studies showed signiﬁcantly
higher total cholesterol, low-density lipoprotein cholesterol
and triglyceride, and lower high-density lipoprotein
cholesterol in individuals with tendon pain/abnormality.
▸ Two of the three studies that examined the correlation
between tendon thickness and lipid levels found a
signiﬁcant positive relationship.
▸ Statin use was associated with Achilles tendon rupture in
women but not men.
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Figure 10 Triglycerides (TG) mean (SD).
Table 2 OR of pain intensity according to TC, HDL-C, LDL-C and
TG
Characteristic OR 95% CI
TC (mmol/L)
<4.7 1 0.4 to 2.7
4.7–5.3 1.0 0.8 to 4.0
>5.3 1.8
HDL-C (mmol/L)
>1.83 1 0.4 to 2.2
1.48–1.83 0.9 1.2 to 6.3
<1.48 2.7
LDL-C (mmol/L)
<2.5 1 0.4 to 2.6
2.5–3.3 1.1 0.7 to 4.2
>3.3 1.7
TG (mmol/L)
<0.72 1 0.7 to 4.0
0.72–1.08 1.7 1.3 to 6.6
>1.08 2.8
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
TC, total cholesterol; TG, triglycerides.
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